



SLOVENSKI STANDARD
oSIST prEN ISO 10993-4:2016
01-februar-2016

Biološko ovrednotenje medicinskih pripomočkov - 4. del: Izbira preskusov za ugotavljanje interakcij s krvjo (ISO/DIS 10993-4:2015)

Biological evaluation of medical devices - Part 4: Selection of tests for interactions with blood (ISO/DIS 10993-4:2015)

Biologische Beurteilung von Medizinprodukten - Teil 4: Auswahl von Prüfungen zur Wechselwirkung mit Blut (ISO 10993-4:2002, einschließlich Änderung 1:2006)

Évaluation biologique des dispositifs médicaux - Partie 4: Choix des essais pour les interactions avec le sang (ISO/DIS 10993-4:2015)

Ta slovenski standard je istoveten z: prEN ISO 10993-4

<https://standards.iteh.ai/catalog/standards/sist/6e7061d7-fb4f-45e2-8d4c-bf0ab220ab4c/sist-en-iso-10993-4-2017>

ICS:

11.100.20	Biološko ovrednotenje medicinskih pripomočkov	Biological evaluation of medical devices
-----------	---	--

oSIST prEN ISO 10993-4:2016

en

DRAFT INTERNATIONAL STANDARD

ISO/DIS 10993-4

ISO/TC 194

Secretariat: DIN

Voting begins on:
2015-11-26Voting terminates on:
2016-02-26

Biological evaluation of medical devices —

Part 4: Selection of tests for interactions with blood

Évaluation biologique des dispositifs médicaux —

Partie 4: Choix des essais pour les interactions avec le sang

ICS: 11.100.20

iTeh Standards (<https://standards.iteh.ai>) Document Preview

[SIST EN ISO 10993-4:2017](https://standards.iteh.ai/catalog/standards/sist/6e7061d7-fb4f-45e2-8d4c-bf0ab220ab4c/sist-en-iso-10993-4-2017)

<https://standards.iteh.ai/catalog/standards/sist/6e7061d7-fb4f-45e2-8d4c-bf0ab220ab4c/sist-en-iso-10993-4-2017>

ISO/CEN PARALLEL PROCESSING

This draft has been developed within the International Organization for Standardization (ISO), and processed under the **ISO lead** mode of collaboration as defined in the Vienna Agreement.

This draft is hereby submitted to the ISO member bodies and to the CEN member bodies for a parallel five month enquiry.

Should this draft be accepted, a final draft, established on the basis of comments received, will be submitted to a parallel two-month approval vote in ISO and formal vote in CEN.

To expedite distribution, this document is circulated as received from the committee secretariat. ISO Central Secretariat work of editing and text composition will be undertaken at publication stage.

THIS DOCUMENT IS A DRAFT CIRCULATED FOR COMMENT AND APPROVAL. IT IS THEREFORE SUBJECT TO CHANGE AND MAY NOT BE REFERRED TO AS AN INTERNATIONAL STANDARD UNTIL PUBLISHED AS SUCH.

IN ADDITION TO THEIR EVALUATION AS BEING ACCEPTABLE FOR INDUSTRIAL, TECHNOLOGICAL, COMMERCIAL AND USER PURPOSES, DRAFT INTERNATIONAL STANDARDS MAY ON OCCASION HAVE TO BE CONSIDERED IN THE LIGHT OF THEIR POTENTIAL TO BECOME STANDARDS TO WHICH REFERENCE MAY BE MADE IN NATIONAL REGULATIONS.

RECIPIENTS OF THIS DRAFT ARE INVITED TO SUBMIT, WITH THEIR COMMENTS, NOTIFICATION OF ANY RELEVANT PATENT RIGHTS OF WHICH THEY ARE AWARE AND TO PROVIDE SUPPORTING DOCUMENTATION.



Reference number
ISO/DIS 10993-4:2015(E)

© ISO 2015

iTeh Standards
(<https://standards.iteh.ai>)
Document Preview

[SIST EN ISO 10993-4:2017](https://standards.iteh.ai/catalog/standards/sist/6e7061d7-fb4f-45e2-8d4c-bf0ab220ab4c/sist-en-iso-10993-4-2017)

<https://standards.iteh.ai/catalog/standards/sist/6e7061d7-fb4f-45e2-8d4c-bf0ab220ab4c/sist-en-iso-10993-4-2017>



COPYRIGHT PROTECTED DOCUMENT

© ISO 2015, Published in Switzerland

All rights reserved. Unless otherwise specified, no part of this publication may be reproduced or utilized otherwise in any form or by any means, electronic or mechanical, including photocopying, or posting on the internet or an intranet, without prior written permission. Permission can be requested from either ISO at the address below or ISO's member body in the country of the requester.

ISO copyright office
Ch. de Blandonnet 8 • CP 401
CH-1214 Vernier, Geneva, Switzerland
Tel. +41 22 749 01 11
Fax +41 22 749 09 47
copyright@iso.org
www.iso.org

Contents

Page

Foreword.....	vi
Introduction.....	viii
1 Scope	1
2 Normative references	1
3 Terms and definitions	1
4 Abbreviated terms	4
5 Types of devices in contact with blood (as categorized in ISO 10993-1:2009)	5
5.1 Non-blood-contact devices	5
5.2 External communicating devices	5
5.2.1 General	5
6 Characterization of blood interactions	7
6.1 General requirements	7
6.2 Categories of tests and blood interactions	12
6.2.1 Recommended tests for interactions of devices with blood	12
6.2.2 Non-contact devices	13
6.2.3 External communicating devices and Implant devices	13
6.2.4 Limitations	13
6.3 Types of tests	14
6.3.1 <i>In vitro</i> tests	14
6.3.2 <i>Ex vivo</i> tests	14
6.3.3 <i>In vivo</i> tests	14
Annex A (informative) Preclinical evaluation of cardiovascular devices and prostheses	16
A.1 General considerations	16
A.1.1 Background	16
A.1.2 Classification	16
A.1.3 Advantages and limitations of animal models	17
A.1.4 Advantages and limitations of <i>in vitro</i> models	17
A.1.5 Test protocols for animal testing	18
A.2 Cannulae used for direct vascular access, and cannulae used for indirect access	18
A.3 Catheters and guide wires	19
A.4 Extracorporeal blood oxygenators, haemodialysis/haemofiltration devices, donor and therapeutic apheresis equipment, devices for adsorption of specific substances from blood	19
A.5 Ventricular-assist devices and total artificial hearts	20
A.6 Heart valve prostheses	20
A.7 Vascular grafts	20
A.8 IVC filters, stents and stented grafts	21
Annex B (informative) Recommended laboratory tests — principles, scientific basis and interpretation	22
B.1 General considerations	22
B.1.1 Background	22
B.1.2 <i>In vitro</i> vs. <i>ex vivo</i> vs. <i>in vivo</i> testing	22

ISO/DIS 10993-4

B.2	Thrombosis	23
B.2.1	Gross analysis - Retrieval and examination of device and autopsy of distal organs	23
B.2.2	Percentage occlusion, surface area covered by thrombus, and thrombus-free surface area.....	23
B.2.3	Light microscopy	23
B.2.4	Scanning electron microscopy (SEM).....	24
B.3	<i>In vitro</i> hemocompatibility	24
B.3.1	Haemolysis – Methods for Testing	24
B.3.2	Coagulation – Methods for Testing	24
B.3.3	Platelets – Methods for Testing.....	27
B.3.4	Hematology – Methods for Testing	29
B.3.5	Complement system – Methods for Testing for C3a and SC5b-9.....	29
B.4	Methodology considerations for testing of plasma factors specific to coagulation, platelet and leucocyte activation, and complement activation, using ELISA (or other similar) techniques	30
B.4.1	General.....	30
B.4.2	General assay methods and documentation	31
B.4.3	Attachments	32
Annex C (informative)	Thrombosis — Methods for <i>in vivo</i> testing	33
C.1	General considerations.....	33
C.2	<i>In vivo</i> implant study of final device in pre-clinical animal study.....	33
C.3	<i>In vivo</i> non-anticoagulated venous implant (NAVI) and anticoagulated venous implant (AVI) thrombogenicity tests	34
Annex D (informative)	Haematology/haemolysis — Methods for testing — Evaluation of haemolytic properties of medical devices and medical device materials.....	39
D.1	General considerations.....	39
D.2	Causes of haemolysis	39
D.2.1	Osmotic pressure (osmotic pressure-induced haemolysis).....	39
D.2.2	Mechanical forces (mechanically-induced haemolysis)	39
D.2.3	Biochemical factors (material-induced haemolysis)	40
D.3	Clinical significance of haemolysis	40
D.3.1	Toxic effects.....	40
D.3.2	Thrombosis and anemia.....	40
D.4	Determining a pass/fail assessment for haemolysis.....	40
D.5	Haemolysis testing — general considerations	41
D.5.1	Methods	41
D.5.2	Blood and blood component preservation	43
D.5.3	Protection of employees handling blood.....	44
D.5.4	Blood collection (phlebotomy)	44
D.5.5	Species selection.....	45
D.5.6	Evaluation of haemolysis – <i>in vitro</i> , <i>ex vivo</i> and <i>in vivo</i> exposure to blood or blood components.....	45
D.5.7	Direct contact versus indirect methods.....	45
Annex E (informative)	Complement — Methods for testing.....	46
E.1	Background information	46
E.2	Complement activation tests and documentation (suggested to consider in reporting complement test results for scientific or regulatory purposes)	47
Annex F (informative)	Less common laboratory tests.....	49
F.1	General.....	49
F.2	Thrombosis	49

F.2.1	Flow reduction.....	49
F.2.2	Gravimetric analysis (thrombus mass)	49
F.2.3	Pressure drop across device.....	50
F.2.4	Adsorbed protein analysis (via antibody binding).....	50
F.2.5	Imaging techniques – angiography, intravascular ultrasound, Doppler ultrasound, CT and MRI	50
F.3	Coagulation	50
F.3.1	Thrombin generation assay using chromogenic substrates.....	50
F.3.2	Fibrinogen and fibrin degradation products (FDP)	50
F.3.3	D-dimer	50
F.4	Platelets.....	51
F.4.1	Platelet adhesion assessments	51
F.4.2	Platelet microparticle formation	51
F.4.3	Gamma imaging of radiolabelled platelets.....	51
F.5	Hematology	51
F.5.1	Leucocyte state and morphology	51
F.5.2	Blood cell adhesion assessments.....	51
F.5.3	Platelet leucocyte complexes (PLCs)	52
F.6	Complement system	52
F.6.1	Complement activation assessment of C5a	52
Annex G (informative)	Tests which are not recommended.....	53
G.1	General	53
G.2	Coagulation	53
G.2.1	APTT (activated prothrombin time), PT (prothrombin time), and TT and (thrombin time)	53
G.3	Platelets.....	53
G.3.1	Platelet aggregation.....	53
G.3.2	Template bleeding time	54
G.3.3	Platelet lifespan.....	54
G.4	Hematology	54
G.4.1	Reticulocyte count.....	54
G.5	Complement system	54
G.5.1	Complement activation assessment of Bb, iC3b, CH-50, C3 convertase, C5 convertase.....	54
Bibliography	55

ISO/DIS 10993-4

Foreword

ISO (the International Organization for Standardization) is a worldwide federation of national standards bodies (ISO member bodies). The work of preparing International Standards is normally carried out through ISO technical committees. Each member body interested in a subject for which a technical committee has been established has the right to be represented on that committee. International organizations, governmental and non-governmental, in liaison with ISO, also take part in the work. ISO collaborates closely with the International Electrotechnical Commission (IEC) on all matters of electrotechnical standardization.

The procedures used to develop this document and those intended for its further maintenance are described in the ISO/IEC Directives, Part 1. In particular the different approval criteria needed for the different types of ISO documents should be noted. This document was drafted in accordance with the editorial rules of the ISO/IEC Directives, Part 2 (see www.iso.org/directives).

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. ISO shall not be held responsible for identifying any or all such patent rights. Details of any patent rights identified during the development of the document will be in the Introduction and/or on the ISO list of patent declarations received (see www.iso.org/patents).

Any trade name used in this document is information given for the convenience of users and does not constitute an endorsement.

For an explanation on the meaning of ISO specific terms and expressions related to conformity assessment, as well as information about ISO's adherence to the WTO principles in the Technical Barriers to Trade (TBT) see the following URL: [Foreword - Supplementary information](#)

The committee responsible for this document is ISO/TC 194, *Biological and clinical evaluation of medical devices*.

This third edition cancels and replaces the second edition (ISO 10993-4:2007, ISO 10993-4: A1:2009), which has been technically revised.

The major technical changes are the following:

- a) some definitions have been revised and new definitions have been added;
- b) Original Tables 1 and 2 have been consolidated into a single new Table 1 with test categories and headers reorganized to emphasize and include (1) material and mechanical-induced haemolysis testing and (2) *in vitro* and *in vivo* testing for assessment of risk for thrombosis;
- c) Original Tables 3 and 4 have been consolidated into a single new Table 2 with a simplified list of suggested and most common tests;
- d) Annex B has been updated to cover only the most common practiced tests for assessing blood interactions;
- e) A new Annex C has been added to cover the topic of *in vivo* thrombosis and methods for testing;
- f) Annex D, previously Annex C Evaluation of the haemolytic properties of medical devices and their components, has been updated and now includes added information on mechanically-induced haemolysis;

- g) New Annex E has been added to cover the topic of Complement testing and best test method practices;
- h) New Annexes F and Annex G are added to present the less common tests used to assess interactions with blood, and, tests not used in preclinical assessment of medical device blood interaction, respectively. Many of these methods were previously included in Annex B;
- i) Subtle language refinements can be found throughout the revised document;
- j) The Bibliography has been reorganized by common subjects of interest and updated with additional and more current references.

ISO 10993 consists of the following parts, under the general title *Biological evaluation of medical devices*:

- Part 1: *Evaluation and testing within a risk management system*
- Part 2: *Animal welfare requirements*
- Part 3: *Tests for genotoxicity, carcinogenicity and reproductive toxicity*
- Part 4: *Selection of tests for interactions with blood*
- Part 5: *Tests for in vitro cytotoxicity*
- Part 6: *Tests for local effects after implantation*
- Part 7: *Ethylene oxide sterilization residuals*
- Part 9: *Framework for identification and quantification of potential degradation products*
- Part 10: *Tests for irritation and delayed-type hypersensitivity*
- Part 11: *Tests for systemic toxicity*
- Part 12: *Sample preparation and reference materials*
- Part 13: *Identification and quantification of degradation products from polymeric medical devices*
- Part 14: *Identification and quantification of degradation products from ceramics*
- Part 15: *Identification and quantification of degradation products from metals and alloys*
- Part 16: *Toxicokinetic study design for degradation products and leachables*
- Part 17: *Method for the establishment of allowable limits for leachable substances*
- Part 18: *Chemical characterization of materials*
- Part 19: *Physico-chemical, morphological and topographical characterization of materials [Technical specification]*
- Part 20: *Principles and methods for immunotoxicology testing of medical devices [Technical specification]*

ISO/DIS 10993-4**Introduction**

The selection and design of test methods for the interactions of medical devices with blood should take into consideration device design, materials, clinical utility, usage environment and risk benefit. This level of specificity can only be covered in vertical standards.

The initial source for developing this part of ISO 10993 was the publication, *Guidelines for blood/material interactions*, Report of the National Heart, Lung, and Blood Institute [16]; chapters 9 and 10. This publication has since been revised [17].

iTeh Standards
(<https://standards.iteh.ai>)
Document Preview

[SIST EN ISO 10993-4:2017](https://standards.iteh.ai/catalog/standards/sist/6e7061d7-fb4f-45e2-8d4c-bf0ab220ab4c/sist-en-iso-10993-4-2017)

<https://standards.iteh.ai/catalog/standards/sist/6e7061d7-fb4f-45e2-8d4c-bf0ab220ab4c/sist-en-iso-10993-4-2017>

Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood

1 Scope

This part of ISO 10993 specifies general requirements for evaluating the interactions of medical devices with blood.

It describes

- a) a classification of medical devices that are intended for use in contact with blood, based on the intended use and duration of contact as defined in ISO 10993-1,
- b) the fundamental principles governing the evaluation of the interaction of devices with blood,
- c) the rationale for structured selection of tests according to specific categories, together with the principles and scientific basis of these tests.

Detailed requirements for testing cannot be specified because of limitations in the knowledge and precision of tests for interactions of devices with blood. This part of ISO 10993 describes biological evaluation in general terms and may not necessarily provide sufficient guidance for test methods for a specific device.

2 Normative references

The following documents, in whole or in part, are normatively referenced in this document and are indispensable for its application. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 10993-1:2009, *Biological evaluation of medical devices — Part 1: Evaluation and testing within a risk management system*

ISO 10993-2:2006, *Biological evaluation of medical devices — Part 2: Animal welfare requirements*

3 Terms and definitions

For the purposes of this part of ISO 10993, the terms and definitions given in ISO 10993-1, ISO 10993-12, and the following apply.

3.1

anticoagulant

agent which prevents or delays blood coagulation

EXAMPLES Heparin, ethylenediaminetetraacetic acid (EDTA), sodium citrate.

3.2

blood/device interaction

any interaction between blood or a blood component and a device

ISO/DIS 10993-4

3.3

coagulation

phenomenon that results from activation of the clotting (coagulation) factor cascade

Note 1 to entry: Factors of the coagulation cascade and fibrinolytic systems can be measured following exposure to devices either *in vitro* or *in vivo*.

3.4

complement system

part of the innate immune system consisting of over 30 distinct plasma proteins, including enzymes, cofactors, and cellular receptors which may be involved in the promotion of thrombosis

Note 1 to entry: Effector molecules produced from complement components are possible components in the phenomena of inflammation, phagocytosis and cell lysis. Complement activation related to immunotoxicity, hypersensitivity and generation of anaphylatoxins is not covered in this part of ISO 10993. (See ISO/TR 10993-20) The focus here in this part of ISO 10993 is complement activation as it can promote and accelerate haemolysis, platelet and leukocyte activation, and thrombosis on device material surfaces. (See also Annex E on complement activation).

3.5

direct blood contact

term used when the device or device material comes into physical contact with blood or blood constituents

3.6

embolization

process whereby a blood thrombus, or foreign object, is carried in the bloodstream and which may become lodged and cause obstructed blood flow downstream

3.7

ex vivo test system

term applied to a test system that shunts blood directly from a human subject or test animal into a test chamber located outside the body

Note 1 to entry: If using an animal model, the blood may be shunted directly back into the animal (recirculating) or collected in test tubes for evaluation (single pass). In either case, the test chamber is located outside the body.

3.8

haematology

study of blood that includes quantification of cellular and plasma components of the blood

3.9

haematocrit

ratio of the volume of erythrocytes to that of whole blood in a given sample

3.10

hemolysis

liberation of haemoglobin from erythrocytes, either by destruction or through a partially damaged but intact cell membrane

3.11**hemocompatible**

term applied to a device or device material wherein contact with blood does not cause any appreciable clinically-significant adverse reactions such as thrombosis, haemolysis, platelet, leukocyte, and complement activation, and/or other blood-associated adverse event

3.12**indirect blood contact**

term used in reference to devices that contact the patient's blood path at one point and serve as conduit for entry into the vascular system; e.g., drug and parenteral nutrition solution delivery devices.

3.13**legally-marketed comparator device (LMCD)**

an approved, long-established, and recognized-to-be-safe medical device used as a reference control in an *in vitro* or *in vivo* safety evaluation of a test device of similar design, material(s), and clinical use

3.14**non-blood-contact**

term used in reference to the nature of the device or material contact with the patient's body where the device or potentially extracted material does not have direct or indirect contact with blood

3.15**colloidal osmotic pressure**

total influence of the proteins or other large molecular mass substances on the osmotic activity of plasma

3.16**platelets**

anuclear, cellular bodies which include platelets and platelet-derived microparticles that are present in blood and contribute to the blood coagulation process by adhering to surfaces, releasing factors, and/or aggregating to form a haemostatic plug

3.17**platelet adherent**

adjective describing a material or device that tends to allow or promote platelets to attach to its surface relative to a negative control, positive control, and/or LMCD upon blood contact due to its surface properties

Note 1 to entry: Platelet adherent does not necessarily mean platelet activating i.e., platelets on a surface may or may not be activated)

3.18**thrombin generating**

adjective describing a material or device that due to its surface properties tends to promote or show increased *thrombin* formation relative to a negative control, positive control, and/or LMCD upon blood contact

3.19**thrombogenic**

adjective describing a material or device that due to its surface properties tends to form or promote *thrombus* formation relative to a negative control, positive control, and/or LMCD upon blood contact

ISO/DIS 10993-4

3.20

thromboembolisation

process where a dislodged thrombus is carried downstream, where it adheres and may cause subsequent vascular blockage or occlusion

3.21

thrombus

coagulated mixture of red cells, aggregated platelets, fibrin and other cellular elements

3.22

thrombosis

formation of a thrombus under *in vivo*, *ex vivo*, or in vitro simulated conditions, caused by activation of the coagulation system and platelets in flowing whole blood

Note 1 to entry: Thrombosis can also occur in regions of a blood vessel or device where there is stasis.

3.23

whole blood

unfractionated blood drawn from a selected donor; the blood may be non-anticoagulated or anticoagulated e.g., contain sodium citrate or heparin as an anticoagulant

4 Abbreviated terms

Bb	enzymatically active fragment of Factor B produced by cleavage (by Factor D) in the activation of the Alternative Pathway
β -TG	beta-thromboglobulin
C4d	degradation product of C4 by classical pathway complement activation
C3a, C5a	complement split products from C3 and C5
CH-50	amount of complement required to lyse 50% of a RBC suspension.
D-Dimer	specific fibrin degradation products (F XIII cross-linked fibrin) consisting of D-fragment dimer
ELISA	enzyme/linked immunosorbent assay
SEM	scanning electron microscopy
FDP	fibrin/fibrinogen degradation products
FPA	fibrinopeptide A
F1.2	the non-catalytic fragment split off from prothrombin in its conversion to thrombin (also referred to as F1+2)
iC3b	inactive form of C3b, a sub-fragment of C3
IFU	Instruction for use
IVC	inferior vena cava